Genomic Predictors of Early Relapse in Immunochemotherapy-Treated Follicular Lymphoma

Follicular lymphoma is the most common indolent non-Hodgkin lymphoma and has a highly variable clinical course. Physicians mainly use clinical factors to distinguish high-risk patients and low-risk patients and to predict overall survival — but with modest utility.

This research project in the University of Iowa/Mayo Clinic Lymphoma SPORE is systematically discovering and validating clinical, tumor and host genetic biomarkers and integrating them into useful clinical information focused on patients with follicular lymphoma with early clinical failures.